Patents by Inventor MATHIAS FERBER

MATHIAS FERBER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS
    Publication number: 20220098270
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Inventors: Leonie ALTEN, Dominik MAURER, Sebastian BUNK, Claudia WAGNER, Mathias FERBER
  • T cell receptors and immune therapy using the same against PRAME positive cancers
    Patent number: 11236145
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 1, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • T CELL RECEPTORS WITH IMPROVED PAIRING
    Publication number: 20210380659
    Abstract: The present invention relates to modified T cell receptor (TCR) ? or ? chains, or heterodimers comprising the same, wherein in the variable domain of said modified ? or ? chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 9, 2021
    Inventors: Sebastian BUNK, Dominik MAURER, Jens FRITSCHE, Claudia WAGNER, Leonie ALTEN, Franziska HOFFGAARD, Mathias FERBER
  • T cell receptors and immune therapy using the same against PRAME positive cancers
    Patent number: 11111286
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: September 7, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • T cell receptors with improved pairing
    Patent number: 11072645
    Abstract: The present invention relates to modified T cell receptor (TCR) ? or ? chains, or heterodimers comprising the same, wherein in the variable domain of said modified ? or ? chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 27, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sebastian Bunk, Dominik Maurer, Jens Fritsche, Claudia Wagner, Leonie Alten, Franziska Hoffgaard, Mathias Ferber
  • T cell receptors and immune therapy using the same against prame positive cancers
    Patent number: 10800832
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: October 13, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • T cell receptors and immune therapy using the same against prame positive cancers
    Patent number: 10759842
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 1, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS
    Publication number: 20200123221
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 31, 2019
    Publication date: April 23, 2020
    Inventors: Leonie ALTEN, Dominik MAURER, Sebastian BUNK, Claudia WAGNER, Mathias FERBER
  • T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS
    Publication number: 20190256572
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Inventors: Leonie ALTEN, Dominik MAURER, Sebastian BUNK, Claudia WAGNER, Mathias FERBER
  • T CELL RECEPTORS WITH IMPROVED PAIRING
    Publication number: 20180162922
    Abstract: The present invention relates to modified T cell receptor (TCR) ? or ? chains, or heterodimers comprising the same, wherein in the variable domain of said modified ? or ? chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.
    Type: Application
    Filed: December 6, 2017
    Publication date: June 14, 2018
    Inventors: SEBASTIAN BUNK, DOMINIK MAURER, JENS FRITSCHE, CLAUDIA WAGNER, LEONIE ALTEN, FRANZISKA HOFFGAARD, MATHIAS FERBER